Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

26 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Second-line chemotherapy with capecitabine (Xeloda) and docetaxel (Taxotere) in previously treated, unresectable adenocarcinoma of pancreas: the final results of a phase II trial.
Katopodis O, Polyzos A, Kentepozidis N, Giassas S, Rovithi M, Bozionelou V, Kalbakis K, Vamvakas L, Mavroudis D, Georgoulias V. Katopodis O, et al. Among authors: bozionelou v. Cancer Chemother Pharmacol. 2011 Feb;67(2):361-8. doi: 10.1007/s00280-010-1329-6. Epub 2010 Apr 29. Cancer Chemother Pharmacol. 2011. PMID: 20428874 Clinical Trial.
Efficacy and treatment tolerance in older patients with NSCLC: a meta-analysis of five phase III randomized trials conducted by the Hellenic Oncology Research Group.
Pallis AG, Karampeazis A, Vamvakas L, Vardakis N, Kotsakis A, Bozionelou V, Kalykaki A, Hatzidaki D, Mavroudis D, Georgoulias V. Pallis AG, et al. Among authors: bozionelou v. Ann Oncol. 2011 Nov;22(11):2448-2455. doi: 10.1093/annonc/mdq772. Epub 2011 Mar 10. Ann Oncol. 2011. PMID: 21393380 Free article.
Salvage treatment in metastatic breast cancer with weekly paclitaxel and bevacizumab.
Polyzos A, Kalbakis K, Kentepozidis N, Giassas S, Kalykaki A, Vardakis N, Bozionelou V, Saloustros E, Kontopodis E, Georgoulias V, Mavroudis D. Polyzos A, et al. Among authors: bozionelou v. Cancer Chemother Pharmacol. 2011 Jul;68(1):217-23. doi: 10.1007/s00280-010-1475-x. Epub 2010 Oct 5. Cancer Chemother Pharmacol. 2011. PMID: 20922389 Clinical Trial.
ZD1839, a novel, oral epidermal growth factor receptor-tyrosine kinase inhibitor, as salvage treatment in patients with advanced non-small cell lung cancer. Experience from a single center participating in a compassionate use program.
Pallis AG, Mavroudis D, Androulakis N, Souglakos J, Kouroussis C, Bozionelou V, Vlachonikolis IG, Georgoulias V. Pallis AG, et al. Among authors: bozionelou v. Lung Cancer. 2003 Jun;40(3):301-7. doi: 10.1016/s0169-5002(03)00079-5. Lung Cancer. 2003. PMID: 12781429 Clinical Trial.
A dose escalation and pharmacokinetic study of biweekly pegylated liposomal doxorubicin, paclitaxel and gemcitabine in patients with advanced solid tumours.
Bozionelou V, Vamvakas L, Pappas P, Agelaki S, Androulakis N, Kalykaki A, Nikolaidou M, Kentepozidis N, Giassas S, Marselos M, Georgoulias V, Mavroudis D. Bozionelou V, et al. Br J Cancer. 2007 Jul 2;97(1):43-9. doi: 10.1038/sj.bjc.6603832. Epub 2007 Jun 5. Br J Cancer. 2007. PMID: 17551496 Free PMC article. Clinical Trial.
26 results